The Cooper Companies, Inc. $COO Shares Sold by Prudential PLC

Prudential PLC cut its stake in The Cooper Companies, Inc. (NASDAQ:COO) by 7.6% during the 4th quarter, HoldingsChannel reports. The fund owned 94,630 shares of the medical device company’s stock after selling 7,837 shares during the period. Prudential PLC’s holdings in Cooper Companies were worth $7,756,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in COO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Cooper Companies by 48.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,407 shares of the medical device company’s stock valued at $1,890,000 after acquiring an additional 7,363 shares in the last quarter. First Trust Advisors LP raised its holdings in Cooper Companies by 115.8% in the second quarter. First Trust Advisors LP now owns 136,334 shares of the medical device company’s stock valued at $9,702,000 after acquiring an additional 73,165 shares in the last quarter. Cresset Asset Management LLC acquired a new stake in Cooper Companies in the second quarter valued at $291,000. Cerity Partners LLC raised its holdings in Cooper Companies by 4.4% in the second quarter. Cerity Partners LLC now owns 17,870 shares of the medical device company’s stock valued at $1,272,000 after acquiring an additional 757 shares in the last quarter. Finally, Daiwa Securities Group Inc. raised its holdings in Cooper Companies by 2.8% in the second quarter. Daiwa Securities Group Inc. now owns 35,839 shares of the medical device company’s stock valued at $2,551,000 after acquiring an additional 973 shares in the last quarter. 24.39% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Cooper Companies posted better-than-expected Q2 results, with EPS of $1.21 topping estimates of $1.10 and revenue of $1.08 billion beating forecasts, while sales rose 7.9% year over year. CooperCompanies Announces Second Quarter 2026 Results
• Positive Sentiment: Management said it reached agreements to resolve substantially all claims tied to the prior fertility media recall, reducing a major legal overhang and supporting investor confidence in the company’s outlook. QuiverQuant article
• Positive Sentiment: Needham reaffirmed a Buy rating on COO and lowered its price target to $86, still implying meaningful upside from current levels. TipRanks analyst update
• Positive Sentiment: Stifel, Baird, and JPMorgan all cut price targets but kept constructive ratings, suggesting analysts see the report as solid even after valuation resets. Benzinga analyst update
• Neutral Sentiment: The company guided FY2026 EPS to $4.58-$4.66, slightly around consensus, which helps confirm expectations but does not point to a major near-term surprise. Earnings report transcript
• Negative Sentiment: JPMorgan lowered its price target on COO from $80 to $71 and kept a Neutral rating, reflecting more cautious expectations despite the stock’s recent strength. JPMorgan price target update

Analyst Ratings Changes

Several analysts have weighed in on COO shares. Stifel Nicolaus lowered their target price on shares of Cooper Companies from $95.00 to $85.00 and set a “buy” rating for the company in a research note on Friday. Needham & Company LLC lowered their target price on shares of Cooper Companies from $101.00 to $86.00 and set a “buy” rating for the company in a research note on Friday. Rothschild & Co Redburn lowered shares of Cooper Companies from a “buy” rating to a “neutral” rating and set a $85.00 target price for the company. in a research note on Wednesday, March 4th. Mizuho set a $85.00 target price on shares of Cooper Companies and gave the company an “outperform” rating in a research note on Thursday. Finally, Barclays boosted their target price on shares of Cooper Companies from $98.00 to $103.00 and gave the company an “overweight” rating in a research note on Friday, March 6th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $82.64.

Cooper Companies Stock Up 8.6%

Cooper Companies stock opened at $67.34 on Friday. The company has a 50-day simple moving average of $65.09 and a 200-day simple moving average of $74.52. The firm has a market capitalization of $13.14 billion, a P/E ratio of 57.07, a P/E/G ratio of 1.60 and a beta of 0.87. The company has a debt-to-equity ratio of 0.22, a quick ratio of 0.79 and a current ratio of 1.34. The Cooper Companies, Inc. has a one year low of $58.89 and a one year high of $89.83.

Cooper Companies (NASDAQ:COO) last released its quarterly earnings results on Thursday, June 4th. The medical device company reported $1.21 EPS for the quarter, topping the consensus estimate of $1.10 by $0.11. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.06 billion. Cooper Companies had a net margin of 5.57% and a return on equity of 10.85%. The company’s quarterly revenue was up 7.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.96 earnings per share. Cooper Companies has set its FY 2026 guidance at 4.580-4.660 EPS. As a group, equities analysts expect that The Cooper Companies, Inc. will post 4.62 earnings per share for the current year.

Cooper Companies Company Profile

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.